KP71

KP71 is an anthracycline-based small molecule antineoplastic agent and an analog of mitoxantrone (MTX) developed by researchers at the University of Bradford. It was designed to address the dose-limiting cardiotoxicity associated with mitoxantrone while retaining its therapeutic efficacy. KP71 exerts its cytotoxic effects by intercalating into DNA, inducing DNA damage, and inhibiting both DNA topoisomerase II alpha (TOP2A) and DNA topoisomerase II beta (TOP2B) enzymes, which are essential for DNA replication and cell division. In preclinical studies, KP71 demonstrated significant antiproliferative activity against breast cancer cell lines (including MDA-MB-468, MDA-MB-231, and MCF7) with a more favorable cytotoxicity profile on non-neoplastic cells and cardiac fibroblasts compared to mitoxantrone, indicating a potentially reduced risk of cardiovascular side effects.